NZ750578A - Viral vaccines - Google Patents
Viral vaccinesInfo
- Publication number
- NZ750578A NZ750578A NZ750578A NZ75057817A NZ750578A NZ 750578 A NZ750578 A NZ 750578A NZ 750578 A NZ750578 A NZ 750578A NZ 75057817 A NZ75057817 A NZ 75057817A NZ 750578 A NZ750578 A NZ 750578A
- Authority
- NZ
- New Zealand
- Prior art keywords
- chikungunya
- zika virus
- smallpox infection
- virus
- viral vaccines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903295A AU2016903295A0 (en) | 2016-08-19 | Viral Vaccines | |
| PCT/AU2017/050879 WO2018032057A1 (en) | 2016-08-19 | 2017-08-18 | Viral vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ750578A true NZ750578A (en) | 2023-05-26 |
Family
ID=61195904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ750578A NZ750578A (en) | 2016-08-19 | 2017-08-18 | Viral vaccines |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10905759B2 (enExample) |
| EP (2) | EP3500280A4 (enExample) |
| JP (1) | JP2019528271A (enExample) |
| KR (1) | KR20190050787A (enExample) |
| CN (1) | CN109862909A (enExample) |
| AR (1) | AR110624A1 (enExample) |
| AU (1) | AU2017313450B2 (enExample) |
| CA (2) | CA3034282A1 (enExample) |
| CL (1) | CL2019000405A1 (enExample) |
| IL (1) | IL264893B (enExample) |
| MA (1) | MA45994A (enExample) |
| MX (1) | MX2019001919A (enExample) |
| MY (1) | MY200887A (enExample) |
| NZ (1) | NZ750578A (enExample) |
| SG (1) | SG11201900814QA (enExample) |
| TW (1) | TWI728173B (enExample) |
| WO (1) | WO2018032057A1 (enExample) |
| ZA (1) | ZA201900641B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117378A1 (en) * | 2018-10-22 | 2020-04-30 | Icellkealex Therapeutics Llc | Mutant vaccinia viruses and use thereof |
| TW202203966A (zh) * | 2020-03-31 | 2022-02-01 | 澳大利亞商賽門蒂斯公司 | 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗 |
| CN112362877B (zh) * | 2020-10-27 | 2024-04-12 | 江苏先声医学诊断有限公司 | 一种mbp重组蛋白以及其应用 |
| KR102864666B1 (ko) * | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU694519B2 (en) * | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
| CN1418951A (zh) | 2001-05-23 | 2003-05-21 | 广州绿健生物技术有限公司 | 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法 |
| PL218318B1 (pl) * | 2002-05-16 | 2014-11-28 | Bavarian Nordic As | Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych |
| EP2269619A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
| KR20040015624A (ko) | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물 |
| DE602004015418D1 (de) * | 2003-02-18 | 2008-09-11 | Helmholtz Zentrum Muenchen | Rekombinantes mva und verfahren zur erzeugung davon |
| EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
| EP1683870A1 (en) * | 2005-01-24 | 2006-07-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vaccines based on the use of MVA |
| GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| AU2011305348A1 (en) | 2010-09-23 | 2013-04-18 | Baxter Healthcare Sa | Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
| WO2014138824A1 (en) * | 2013-03-15 | 2014-09-18 | Sementis Limited | Immune modulation |
| PL3063278T3 (pl) * | 2013-11-01 | 2018-08-31 | Sementis Limited | Wytwarzanie wektora wirusowego |
| WO2016086980A1 (en) * | 2014-12-02 | 2016-06-09 | Consejo Superior De Investigaciones Cientificas | Vaccine composition |
| WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
-
2017
- 2017-08-18 NZ NZ750578A patent/NZ750578A/en unknown
- 2017-08-18 JP JP2019508842A patent/JP2019528271A/ja active Pending
- 2017-08-18 EP EP17840633.6A patent/EP3500280A4/en not_active Withdrawn
- 2017-08-18 EP EP23215911.1A patent/EP4331676A3/en active Pending
- 2017-08-18 AR ARP170102311A patent/AR110624A1/es unknown
- 2017-08-18 TW TW106128111A patent/TWI728173B/zh not_active IP Right Cessation
- 2017-08-18 MX MX2019001919A patent/MX2019001919A/es unknown
- 2017-08-18 MA MA045994A patent/MA45994A/fr unknown
- 2017-08-18 IL IL264893A patent/IL264893B/en unknown
- 2017-08-18 KR KR1020197007662A patent/KR20190050787A/ko not_active Ceased
- 2017-08-18 AU AU2017313450A patent/AU2017313450B2/en active Active
- 2017-08-18 CN CN201780063830.0A patent/CN109862909A/zh active Pending
- 2017-08-18 CA CA3034282A patent/CA3034282A1/en active Pending
- 2017-08-18 MY MYPI2019000845A patent/MY200887A/en unknown
- 2017-08-18 US US16/325,539 patent/US10905759B2/en active Active
- 2017-08-18 WO PCT/AU2017/050879 patent/WO2018032057A1/en not_active Ceased
- 2017-08-18 CA CA3265584A patent/CA3265584A1/en active Pending
- 2017-08-18 SG SG11201900814QA patent/SG11201900814QA/en unknown
-
2019
- 2019-01-30 ZA ZA2019/00641A patent/ZA201900641B/en unknown
- 2019-02-14 CL CL2019000405A patent/CL2019000405A1/es unknown
-
2020
- 2020-12-22 US US17/130,165 patent/US20210113684A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210113684A1 (en) | 2021-04-22 |
| EP3500280A4 (en) | 2020-05-13 |
| EP4331676A3 (en) | 2024-05-15 |
| MY200887A (en) | 2024-01-22 |
| IL264893A (enExample) | 2019-04-30 |
| BR112019003181A2 (pt) | 2019-07-16 |
| MX2019001919A (es) | 2019-09-04 |
| CL2019000405A1 (es) | 2019-06-14 |
| RU2019107582A3 (enExample) | 2021-03-31 |
| US20200009245A1 (en) | 2020-01-09 |
| JP2019528271A (ja) | 2019-10-10 |
| AU2017313450B2 (en) | 2024-02-15 |
| AR110624A1 (es) | 2019-04-17 |
| TWI728173B (zh) | 2021-05-21 |
| SG11201900814QA (en) | 2019-03-28 |
| MA45994A (fr) | 2021-03-17 |
| EP4331676A2 (en) | 2024-03-06 |
| WO2018032057A1 (en) | 2018-02-22 |
| IL264893B (en) | 2022-08-01 |
| RU2019107582A (ru) | 2020-09-21 |
| EP3500280A1 (en) | 2019-06-26 |
| CA3034282A1 (en) | 2018-02-22 |
| ZA201900641B (en) | 2025-10-29 |
| KR20190050787A (ko) | 2019-05-13 |
| TW201809273A (zh) | 2018-03-16 |
| AU2017313450A1 (en) | 2019-02-28 |
| US10905759B2 (en) | 2021-02-02 |
| CN109862909A (zh) | 2019-06-07 |
| CA3265584A1 (en) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| ZA201900641B (en) | Viral vaccines | |
| EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
| MX2020013153A (es) | Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana. | |
| CO7160021A2 (es) | Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| EP4043031A3 (en) | Zika viral antigen constructs | |
| IN2015DN02546A (enExample) | ||
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
| MX380455B (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos. | |
| PH12017500419A1 (en) | Recoded arbovirus and vaccines | |
| PH12017501100B1 (en) | Recombinant swinepox virus and vaccines | |
| MY192543A (en) | Dengue virus vaccine compositions and methods of use thereof | |
| PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| PH12018502460B1 (en) | Arthrogenic alphavirus vaccine | |
| PH12020551944A1 (en) | Reverse peptide vaccine | |
| EA201401044A1 (ru) | Модифицированный вирус болезни марека и вакцины на его основе | |
| CA3009928A1 (en) | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine | |
| BR112018009032A8 (pt) | vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração | |
| EA201790506A1 (ru) | Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) |